Cystic Fibrosis - Heat Map and Analysis

ReportsWorldwide has announced the addition of a new report title Cystic Fibrosis - Heat Map and Analysis to its growing collection of premium market research reports.

Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body’s epithelial cells, and result in the buildup of a thick and sticky mucus in the lungs and pancreas. Historically therapeutic options have focused heavily on treating the symptoms, but despite being clinically and commercially successful have failed to address the faulty CFTR proteins that cause the disease. This unmet need has led to the development of CFTR modulators.

Scope of the Report:

- To what extent is the CF market landscape expected to change with the introduction of new CFTR modulators?

- What are the clinical characteristics of currently approved therapies for CF, in terms of specific safety and efficacy parameters?

- What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?

- How will current late-stage CFTR modulators affect the market for symptomatic therapies, and are they able to yield comparable clinical efficacy results to Kalydeco?

- How will the influx of tobramycin generics affect the competitive landscape?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6867

Reasons to buy

- Understand the current clinical landscape by considering the treatment options available for each patient segment.

- Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.

- Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.

- Understand the relative strengths and weaknesses of the studies used to gather these data.

- Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.

- Assess your own pipeline programs in light of these benchmarks in order to optimally position them and maximize uptake by clinicians.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/cystic-fibrosis-heat-map-and-analysis

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.